Margin Breakdown
29.03
Profit Margin
22.83
Operating Margin
27.29
EBITDA Margin
| Operating Margin | 22.83 | |
| EBITDA Margin | 27.29 | |
| Gross Margin | 101.75 | |
| Profit Margin | 29.03 |
Should you continue to rely on Regeneron Pharmaceuticals (NASDAQ:REGN) management?
 | By Raphi Shpitalnik | Macroaxis Story |
Regeneron Pharmaceuticals Enterprise Value is quite stable at the moment as compared to the past year. The company's current Enterprise Value is estimated at 37.07 Billion. Free Cash Flow is projected to rise to about 933.6 M this year, although the value of Revenue Per Employee will most likely fall to about 840.9 K. The underlying goal of this short thesis is to outline Regeneron as an investment oportunity for September. We will inspect why recent Regeneron Pharmaceuticals price moves suggest a bounce in September.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Over 68.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Institutional ownership of Regeneron Pharmaceuticals refers to the amount of Regeneron Pharmaceuticals equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Regeneron, including its current ownership diagnostics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Regeneron Pharmaceuticals. Your research has to be compared to or analyzed against Regeneron Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Regeneron Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Regeneron Pharmaceuticals.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Regeneron Pharmaceuticals. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Regeneron Pharmaceuticals
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Regeneron Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Regeneron Pharmaceuticals's Liquidity
Regeneron Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Regeneron Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Regeneron Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Regeneron Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Regeneron Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Regeneron Pharmaceuticals's total debt and its cash.
Regeneron Pharmaceuticals Gross Profit
Regeneron Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Regeneron Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Regeneron Pharmaceuticals Gross Profit growth over the last 10 years. Please check Regeneron Pharmaceuticals' gross profit and other fundamental indicators for more details.
What is driving Regeneron Pharmaceuticals Investor Appetite?
The latest bullish price patterns experienced by current Regeneron Pharmaceuticals shareholders created some momentum for institutional investors as it was traded today as low as 636.1 and as high as 654.46 per share. The company executives have been very successful in rebalancing the company assets at opportune times to take advantage of market volatility in July. The stock standard deviation of daily returns for 30 days investing horizon is currently 2.45. The current volatility is consistent with the ongoing market swings in July 2020 as well as with Regeneron Pharmaceuticals unsystematic, company-specific events.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Regeneron Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.